Kentaro Yoshimatsu
Oprichter bij Rin Institute, Inc.
Actieve functies van Kentaro Yoshimatsu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Anaeropharma Science, Inc.
 Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Directeur/Bestuurslid | - | - |
Rin Institute, Inc.
 Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Directeur/Bestuurslid | 21-01-2016 | - |
| Oprichter | 21-01-2016 | - | |
| President | 21-01-2016 | - |
Loopbaan van Kentaro Yoshimatsu
Eerdere bekende functies van Kentaro Yoshimatsu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EISAI CO., LTD. | Hoofd Techniek/Wetenschap/O&O | 07-01-2010 | 30-09-2011 |
| Corporate Officer/Principal | 07-01-2010 | 16-09-2010 | |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | President | 06-07-2011 | - |
Opleiding van Kentaro Yoshimatsu
| University of Tokyo | Doctorate Degree |
Statistieken
Internationaal
| Japan | 5 |
| Verenigde Staten | 2 |
Operationeel
| President | 2 |
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Health Technology |
- Beurs
- Insiders
- Kentaro Yoshimatsu
- Ervaring
